Internet
Veodia
San Mateo, Calif., software-as-a-service video company Veodia has raised $8.3 million in Series A funding. Investors included Clearstone Venture Partners of Santa Monica, Calif., D.E. Shaw & Co. LP of New York and an angel group led by iParadigms LLC chairman Steven Berger. The company's technology enables streaming of high-quality video from a standard browser. It will use the new financing to support product development and to add staff.
Software
FireEye
FireEye Inc., a maker of security technology for remotely controlled computers, has raised a $14.5 million Series C round. DAG Ventures of San Francisco led the funding, joined by the returning Norwest Venture Partners and Sequoia Capital LLP, both of Menlo Park, Calif., Jafco Ventures of San Jose, Calif., SVB Capital of Santa Clara, Calif., and new strategic investor Juniper Networks Inc. of Sunnyvale, Calif. The deal brings total investment in the four-year-old Milpitas, Calif., company to $34.5 million. FireEye makes security technology designed to augment firewall products by identifying malicious software.
Medical devices
Veran Medical Technologies
St. Louis medical device startup Veran Medical Technologies Inc. has secured $4.75 million to drive adoption of its IG4 delivery system for minimally invasive biopsy and removal of cancer. Prolog Ventures, also of St. Louis, led the round, joined by Advantage Capital Partners of New York and unnamed existing private investors. The company's Veran IG4 system and instruments target very small lesions, to indentify cancer at a preliminary early stage. The system aims to enable clinicians to treat patients earlier in the disease cycle without subjecting them to unnecessary complication risk.
Biotech
Revance
Revance Therapeutics Inc. of Mountain View, Calif., has announced the completion of an $8 million Series C add-on financing. The funding brings the Series C to $51.2 million, following a $43.2 million closing in December 2007. Bio*One Capital of Redwood City, Calif., led the round, joined by returning investors Essex Woodlands Healthcare Ventures, Vivo Ventures, Technology Partners and Palo Alto Investors, all of Palo Alto, Calif. Shepherd Ventures of San Diego and new investors Medicis Pharmaceutical Cor. of Scottsdale, Ariz., and Pac-Link Ventures of Taiwan were also involved. The capital will enable Revance to expand its botulinum toxin clinical programs and product pipeline. Revance is developing aesthetic medicine category products; its platform technology allows non-invasive transcutaneous delivery of botulinum toxin molecules across skin and barrier membranes without patches, needles or other invasive procedures.
Continue reading below
